Cerecor Inc. (NASDAQ:CERC) – Stock analysts at Zacks Investment Research raised their FY2017 earnings estimates for shares of Cerecor in a note issued to investors on Thursday. Zacks Investment Research analyst D. Bautz now anticipates that the company will post earnings per share of $0.83 for the year, up from their previous forecast of ($0.80). Zacks Investment Research also issued estimates for Cerecor’s Q4 2017 earnings at ($0.13) EPS, FY2018 earnings at ($0.59) EPS and FY2019 earnings at ($0.61) EPS.
Several other research firms have also issued reports on CERC. ValuEngine raised shares of Cerecor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 7th. TheStreet raised shares of Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.truebluetribune.com/2017/11/14/fy2017-earnings-forecast-for-cerecor-inc-cerc-issued-by-zacks-investment-research.html.
Shares of Cerecor (CERC) opened at $1.01 on Monday. Cerecor has a 52-week low of $0.34 and a 52-week high of $5.60. The stock has a market cap of $26.05, a price-to-earnings ratio of 100.00 and a beta of 2.13.
Cerecor (NASDAQ:CERC) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.15. Cerecor had a net margin of 51.71% and a return on equity of 212.90%. The company had revenue of $0.16 million during the quarter.
In other news, major shareholder Armistice Capital Master Fund bought 219,792 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was acquired at an average cost of $0.60 per share, for a total transaction of $131,875.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 1,638,693 shares of company stock valued at $1,053,475 over the last 90 days. Insiders own 10.70% of the company’s stock.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.